Inheritance of a mutation in breast cancer susceptibility gene 1 (BRCA1) confers a high risk of breast and ovarian cancer, and tumors in carriers of BRCA1 gene mutations are characterized by excessive genome instability. The BRCA1 protein has been implicated in several aspects of genome stability including checkpoint promotion, DNA cross-link repair, replication-fork stability and DNA double-strand break (DSB) repair 1-3 . In DSB repair, BRCA1 is most prominently associated with homologous recombination (HR), in which it promotes the essential step of DNA resection by opposing the block on resection contributed by the p53-binding protein 53BP1 and its effector proteins (reviewed in refs. 3,4). In the absence of BRCA1, DSBs are repaired by toxic nonhomologous end joining (NHEJ) 5 . BRCA1 associates with the resection protein CtIP and subsequently relieves the 53BP1 block 6 , but how BRCA1 contributes to this process is not known.
a r t i c l e s
Inheritance of a mutation in breast cancer susceptibility gene 1 (BRCA1) confers a high risk of breast and ovarian cancer, and tumors in carriers of BRCA1 gene mutations are characterized by excessive genome instability. The BRCA1 protein has been implicated in several aspects of genome stability including checkpoint promotion, DNA cross-link repair, replication-fork stability and DNA double-strand break (DSB) repair [1] [2] [3] . In DSB repair, BRCA1 is most prominently associated with homologous recombination (HR), in which it promotes the essential step of DNA resection by opposing the block on resection contributed by the p53-binding protein 53BP1 and its effector proteins (reviewed in refs. 3, 4) . In the absence of BRCA1, DSBs are repaired by toxic nonhomologous end joining (NHEJ) 5 . BRCA1 associates with the resection protein CtIP and subsequently relieves the 53BP1 block 6 , but how BRCA1 contributes to this process is not known.
In people with familial breast and ovarian cancer, pathogenic and unclassified substitution variants in the BRCA1 gene have been found across the region encoding the first 100 amino acids (aa). This part of BRCA1 contacts its heterodimeric binding partner, the BRCA1-associated RING-domain protein, BARD1, and E2 ubiquitin (Ub)-conjugating enzymes, thereby allowing BRCA1-BARD1 to function as an E3 Ub ligase in the transfer of Ub from E2-conjugating enzymes to target proteins 7 . Several targets have been proposed, and recently BRCA1-mediated ubiquitination of histone H2A has been mapped 8 . However the role, if any, of the BRCA1 E3 Ub ligase activity in DNA repair has been controversial [9] [10] [11] . Evidence from Brca1-deficient mice has suggested that H2A ubiquitination regulates global heterochromatin integrity and, through transcriptional repression of satellite RNA, is responsible for multiple disparate cellular functions of Brca1, including the promotion of genomic integrity 9 . How increased satellite RNA affects HR repair is not clear, and the phenomenon of increased satellite RNA expression has not been universally observed in Brca1-deficient models 12 . Indeed, other models of Brca1 dysfunction have suggested a restricted role, or no role, for its biochemical function in DNA repair 10, 11 .
Here, we sought to investigate the role of the BRCA1-BARD1 Ub ligase activity in the DNA-damage response in human cells. Our data suggest a model in which chromatin modification by BRCA1-BARD1 E3 Ub ligase activity repositions 53BP1 and drives completion of resection through promoting the activity of the SWI/SNF-related matrixassociated actin-dependent regulator of chromatin (SMARCAD1).
Nevertheless minimal BRCA1-BARD1 N-terminal fragments exhibit base-level Ub ligase activity 16, 17 , thus indicating that the elements necessary for Ub transfer are present within the polypeptides.
To identify a possible Ub-binding interface, we overlaid the RNF4-RNF4-Ub~E2 structure (PDB 4AP4 (ref. 13) ) onto N-terminal BRCA1-BARD1 (PDB 1JM7 (ref. 18) ). In the superposition, BARD1 residues 91-99 are in a similar location to the RNF4 residue Y193, which engages Ub13. A mutational scan across the BARD1 region revealed that a heterodimer bearing a substitution at R99 exhibited decreased activity ( Supplementary Fig. 1a,b) . Substitution of R99 to a lysine was tolerated, but the activity of the heterodimer with glutamate (R99E) was severely impaired for all Ub-conjugating enzymes of the Ub-conjugating enzyme 2D (UBE2D) family ( Fig. 1a and Supplementary Fig. 1c-e) . Substitutions at R99 did not affect BARD1's interaction with BRCA1 (Fig. 1b) , but the R99E-mutant heterodimer showed a weaker interaction with conjugation-proficient E2 (Supplementary Fig. 1f ).
In the superimposition, R99 of BARD1 is predicted to be close to the D32 side chain of Ub (Supplementary Fig. 1g ). To test whether R99 of BARD1 contacts Ub, we generated a D32R mutation in Ub. This mutant, compared with wild-type (WT) Ub, was processed slightly less well by the BRCA1-BARD1 heterodimer, but the weak catalytic activity of the R99E BARD1-mutant heterodimer substantially improved with D32R Ub (Fig. 1c) , thus suggesting contact with Ub contributes to activity. Transfer reactions of Ub from UBE2D1 or UBE2D3 E2 enzymes to free lysine revealed decreased discharge rates with the R99E heterodimer than with WT proteins ( Fig. 1d and Supplementary Fig. 1h ). Thus, R99 of BARD1 promotes heterodimer interaction with the Ub~E2 thioester conjugate through Ub and is required to promote the discharge of Ub from the E2 contacting BRCA1.
We noted that other type 1 RING E3 ligases carry positively charged residues (arginine or lysine) at positions analogous to R99 of BARD1 ( Fig. 2a and Supplementary Fig. 2a ). For example, in the heterodimeric npg a r t i c l e s complex of B cell-specific Moloney murine leukemia virus integration site 1 (BMI1; also known as Polycomb-group RING-finger protein 4 (PCGF4)) with RING1B, the 'inactive' partner, BMI1, has an equivalent lysine, K73, whereas the protomer contacting the E2, RING1B, lacks a similarly located charged residue (as does BRCA1). We mutated K73E in BMI1 and R76A in RAD18. Whereas ectopically expressed WT RAD18 induced PCNA monoubiquitination and also potentiated PCNA monoubiquitination after UV exposure, the R76A mutant did not (Fig. 2b) . Similarly, the K73E BMI1-RING1B heterodimer was unable to catalyze monoubiquitination of H2A in nucleosomes in vitro ( Fig. 2c ; copurification in Supplementary Fig. 2b ). Fig. 2c -e). These data are consistent with the effects of inhibition of RING1A and RING1B 19 . We suggest that a charged interface between type 1 dimeric RING E3 ligases and the donor Ub activates the E2~Ub thioester. In the two heterodimeric complexes, this key interface is provided by protomers previously described as simply scaffold proteins, BARD1 and BMI1.
Ligase activity is required for a subset of BRCA1 responses
To address possible roles of the BRCA1-BARD1 Ub ligase activity, we depleted HeLa cells of endogenous BARD1 and expressed short interfering RNA (siRNA)-resistant full-length WT BARD1 cDNA or mutant forms bearing BARD1 amino acid substitutions R99E or L44R (illustrated in Fig. 3a ). L44R introduces a large hydrophilic residue in the hydrophobic helical face of BARD1, thereby preventing interaction with BRCA1 (ref. 20) . Complementation of cells with L44R BARD1 did not support heterodimer formation or heterodimer stability, or promote endogenous BRCA1 localization to irradiationinduced foci (IRIF) ( Supplementary Fig. 3a-c) . In contrast, R99E BARD1 retained dimerization with BRCA1 and promoted both BRCA1 stability and localization to IRIF ( Supplementary Fig. 3a-c) .
Purified complexes of neither R99E BARD1 nor L44R BARD1 exhibited Ub ligase activity ( Supplementary Fig. 3d ). Thus, L44R BARD1 disrupts both heterodimer formation and ligase activity in cells, whereas the R99E BARD1 variant is ligase defective but promotes heterodimer formation.
To differentiate potential roles of ligase activity from those of the heterodimer in DNA repair, we compared the survival of cells depleted of endogenous BARD1 and complemented with the separation-of-function variants in response to various DNA-damaging agents. BARD1 depletion or complementation with L44R BARD1 resulted in sensitivity to each DNA-damaging agent tested, and complementation with the WT BARD1 protein restored resistance (Fig. 3b) . Strikingly R99E BARD1-complemented cells exhibited resistance to some agents but not to others. They were resistant to agents that stall or slow replication forks (hydroxyurea (HU) and aphidicolin) and to the intrastrandcross-linking agent cisplatin, but they were sensitive to camptothecin (a topoisomerase I poison), etoposide (a topoisomerase II poison), olaparib (AZD-2281, an inhibitor of poly(ADP-ribose) polymerase) and irradiation (Fig. 3b) . These data prompted us to revisit the I26A substitution of BRCA1 that disrupts interaction with E2 conjugating enzymes (ref. 7 and Supplementary Fig. 3e ). Cells depleted of endogenous BRCA1 and complemented with I26A BRCA1 were also sensitive to olaparib (Fig. 3c) , thus supporting the notion that the BRCA1-BARD1 Ub ligase activity supports olaparib resistance.
Ligase activity promotes 53BP1 repositioning and resection
The sensitivities of ligase-defective cells suggest a role in the promotion of HR, a process begun by resection of DNA ends. To interrogate the HR pathway, we first examined the single-stranded DNA-binding protein replication protein A (RPA), which forms foci after irradiation and is indicative of resection. Cells complemented with R99E BARD1 or L44R BARD1 exhibited decreased numbers, size and intensity of RPA foci and also exhibited decreased foci of the human homolog of yeast radiation mutant 51 (RAD51), compared with those in WT BARD1-complemented cells ( Fig. 4a and Supplementary  Fig. 4a ). These data suggest that ligase activity relates to the role of BRCA1 in promoting DNA resection before formation of the RAD51 nucleofilament in HR.
53BP1 and its effector proteins block DNA resection in the absence of BRCA1 (ref. 4) . As anticipated, depletion of 53BP1 alleviated the requirement for BRCA1-BARD1 Ub ligase activity in olaparib and camptothecin resistance, increased RAD51 and RPA foci after irradiation and improved repair of an integrated HR substrate in a manner dependent on the CtBP-interacting protein and nuclease (CtIP) (Fig. 4b and Supplementary Fig. 4b-f) . Depletion of the 53BP1 effector proteins, human REV7 (also known as MAD2 mitotic arrest deficient-like 2 (MAD2L2)) 21, 22 or Artemis 23 similarly improved survival of R99E BARD1-complemented cells after treatment with irradiation, olaparib or camptothecin to differing degrees, depending on the agent (Supplementary Fig. 5a-c) .
These data provide what is, to our knowledge, the first evidence that the Ub ligase activity of BRCA1-BARD1 contributes to the a r t i c l e s function of BRCA1 in DNA resection and, consistently with the described relationship between BRCA1 and 53BP1, it can be bypassed by loss of 53BP1 or its effector proteins. In contrast, the resistance of BRCA1-depleted cells to HU was not restored by 53BP1 depletion (Fig. 4c) , a result consistent with the notion that the Ub-ligase-independent functions of BRCA1 do not include interaction with 53BP1. The recruitment of BRCA1 into the core of IRIF is associated with the eviction of 53BP1 to the periphery of the foci and the concurrent RPA recruitment to the core 24, 25 . We measured the distribution of 53BP1 in foci associated with BRCA1 in BARD1-depleted cells complemented with WT or R99E BARD1 protein. Whereas the distribution of BRCA1 within IRIF in these cells was similar, the cells complemented with R99E BARD1 showed markedly decreased eviction of 53BP1 to the periphery (Fig. 4d) . Thus, the ligase activity plays a role in 53BP1 repositioning at IRIF.
Ligase activity in resection is needed after HR commitment
Resection consists of an initiation step, requiring the nuclease CtIP and meiotic recombination 11 homolog A (MRE11) endonuclease activity, and an elongation stage, requiring MRE11 exonuclease activity and then extension by exonuclease 1 (EXO1) or Bloom Syndrome RecQ helicase (BLM) and DNA replication helicase/nuclease 2 (DNA2) (reviewed in ref. 26) . To assess when the BRCA1-BARD1 Ub ligase activity is required in resection, we incubated cells with bromodeoxyuridine (BrdU) and then measured track lengths of the exposed BrdU epitope, which were indicative of single-stranded DNA as a measure of resected DNA after olaparib exposure (as described in ref. 27 ). R99E BARD1-complemented cells or BARD1-depleted cells showed shorter resection lengths, which were similar to those of cells exposed to the MRE11 exonuclease inhibitor MIRIN but were not as severely truncated as those in cells exposed to the MRE11 endonuclease inhibitor PFM01 (Fig. 5a) . These data suggest that some resection a r t i c l e s occurs in BRCA1-BARD1 ligase-defective cells after the requirement for MRE11 endonuclease activity. Incomplete resection after commitment results in irradiation sensitivity, which is largely rescued by the inhibition of resection initiation through CtIP depletion, because loss of CtIP prevents HR commitment but allows repair by NHEJ 28 . We found that depletion of CtIP improved the repair of an NHEJ substrate but not an HR substrate in BARD1-depleted cells (Fig. 5b-d) and restored the majority of the resistance of R99E BARD1-complemented or BARD1-depleted cells to irradiation (Fig. 5e) . These data functionally confirm that the requirement for BRCA1 ligase activity occurs after HR commitment. They also suggest that in BRCA1-BARD1-deficient cells, or in cells lacking its Ub ligase function, most sensitivity to irradiation is a consequence of incomplete resection and poor NHEJ, and a smaller proportion is due to HR deficiency.
An H2A-Ub fusion promotes DNA resection
We next assessed possible targets of BRCA1-BARD1 ubiquitination including 53BP1, its effector proteins and histones. We irradiated cells transfected with constructs expressing histidine-Myc-tagged Ub and BARD1 and purified covalently bound Ub conjugates under highly denaturing conditions. 53BP1 and H2A were enriched in WT BARD1-expressing cells but were decreased in cells expressing R99E BARD1 mutants (Fig. 6a) , thus suggesting that BRCA1-BARD1 E3 ligase activity results in ubiquitination of these two proteins. H2A modification was visible in the R99E BARD1 lane after high exposure, thus indicating an additional, expected, BRCA1-BARD1-independent modification.
H2A has previously been identified as a BRCA1-BARD1 Ub ligase target 8, 9, 17 , where it is modified at its C-terminal lysines K125, K127 and K129 (ref. 8) . We attempted to replace a proportion of endogenous H2A (which is expressed from several genes) with mutant histone by generating stable cell lines bearing H2A K125R, K127R and K129R mutations. However, the expression of the H2A mutants had no effect on olaparib sensitivity, thus suggesting either that modification elsewhere is important for resistance or that insufficient mutant histone incorporation was achieved (Supplementary Fig. 6a,b) .
As an alternative approach, we generated a H2A mutant-Ub fusion protein and determined whether it could complement BARD1-depleted cells. In the H2A fusion, we mutated lysines 13, 15, 118, 119, 125, 127 and 129 to arginines to interrogate the function of the fused Ub in the absence of endogenous ubiquitination events; we also mutated the Ub itself at all seven lysines to prevent chain formation. Both exogenous H2A and the H2A-Ub fusion were incorporated into chromatin (Fig. 6b) . In agreement with the previous finding that expression of a similar fusion improves repair of a gene-conversion substrate in BRCA1-deficent cells 9 , we confirmed that expression of the H2A-Ub protein promoted repair of a gene-conversion substrate in BARD1-depleted cells (Supplementary Fig. 6c,d) . To address whether H2A-Ub has the ability to restore physiological HR, we examined the formation of RAD51 foci in BARD1-depleted cells. In a dose-response experiment, we found that H2A-Ub levels correlated with restoration of RAD51 foci, thus suggesting that greater incorporation of the protein into chromatin resulted in greater rescue ( Fig. 6c  and Supplementary Fig. 6e) . Moreover, neither the degree of gene conversion nor the number of RAD51 foci in cells expressing H2A-Ub was further increased when 53BP1 was depleted ( Supplementary  Fig. 6d,f) , thus indicating that H2A-Ub expression and the removal of 53BP1 had similar effects. Consistently with an ability to complement the lack of BRCA1-BARD1 ligase activity in HR, expression of H2A-Ub promoted the survival of BARD1-depleted cells after treatment with olaparib and camptothecin but did not restore the resistance to HU (Supplementary Fig. 6g-i) , a result consistent with the requirement for BRCA1-BARD1 ligase activity. As anticipated, both the drug resistance and restoration of RAD51 conferred by H2A-Ub required CtIP (Supplementary Fig. 6j,k) . Together, these data provide strong evidence that the H2A-Ub fusion restored physiological resection and HR in the BARD1-depleted cells.
We then examined the specifics of the H2A-Ub fusion in more detail. We tested an alternative globular protein, blue fluorescent protein (BFP), fused to the C terminus of H2A. This fusion was unable to rescue drug resistance or restore RAD51 foci in BARD1-depleted cells (Fig. 6d and Supplementary Fig. 6g,i) thus indicating that not all C-terminal protein fusions were able to complement. We addressed whether the location of the Ub might be critical and compared H2A (again bearing K-to-R mutations at positions 13, 15, 118, 119, 125, 127 and 129) in which Ub had been fused to the N terminus, the C terminus or both termini. The N-terminal fusion of Ub to H2A slightly improved the numbers of RAD51 foci in BARD1-deleted cells, whereas RAD51 foci in cells expressing H2A with Ub fused to the C terminus or to both ends were fully restored (Fig. 6d) . These data suggest that a C-terminal Ub fusion is most able to promote formation of RAD51 foci and that Ub fused to the N terminus does not inhibit the restoration of HR promoted by the C-terminal fusion. Together, these data indicate that incorporation of H2A-Ub into chromatin either supports a function similar to that of the BRCA1-BARD1 ligase or contributes an indirect role that overcomes the need for heterodimer activity.
We next addressed how BRCA1-BARD1 ligase activity or Ubmodified nucleosomes might affect 53BP1 and resection. We assessed whether H2A-Ub fusions inhibit 53BP1 accumulation to IRIF, whether BRCA1-BARD1 depletion results in expression of epigenetically silenced genes or whether depletion of a repressive chromatin factor (chromodomain helicase DNA binding protein 3 (CHD3), part of the repressive nucleosome-remodeling deacetylase complex) might relieve the requirement for BRCA1-BARD1 (Supplementary Fig. 7a-f and Supplementary Note). These potential mechanisms were not supported by evidence from our investigations.
SMARCAD1 is part of the BRCA1-BARD1 ligase pathway
We then focused on the proteins involved in the later stages of DNA resection and observed decreased BLM recruitment to IRIF in BARD1-depleted cells (Supplementary Fig. 7g ). Unlike the requirement for BRCA1-BARD1 ligase activity, the requirement for late-stage resection enzymes in HR cannot be overcome by a loss of 53BP1 (refs. 29,30) , thus leading us to consider the phenomenon of poor BLM recruitment as an indication of a defect occurring earlier in the process.
In yeast, the ATP-dependent chromatin remodeler function unknown now 30 (Fun30) promotes the activity of Exo1 and Sgs1 (BLM) in resection [31] [32] [33] . The mammalian homolog SMARCAD1 also promotes resection 32 , and the protein has two Ub-binding CUE domains (which are similar to a domain in the yeast Cue1 protein) 34 ( Fig. 7a) . To test whether this protein might link BRCA1-BARD1-dependent chromatin modification to 53BP1 repositioning and DNA resection, we examined the interaction of the SMARCAD1 CUE domains with nucleosomes bearing H2A-Ub. Nickel beads bound to hexahistidine (His 6 )-tagged SMARCAD1 CUE domains pulled down H2A-Ub but not H2A, whereas SMARCAD1 CUE-domain mutants (termed CUEm, with Ub-contacting phenylalanine, alanine and leucine residues, as previously described 35 , changed to glutamate) purified neither histone (Fig. 7b). 
npg a r t i c l e s
We next addressed SMARCAD1 recruitment and introduced siRNA-resistant plasmids encoding full-length SMARCAD1 or CUEm SMARCAD1 into SMARCAD1-depleted cells (Fig. 7c) . WT SMARCAD1 localized to laser-induced sites of DNA damage decorated with phosphorylated histone H2AX (γ-H2AX) (Fig. 7d) . Its accumulation was decreased, but not lost, when BARD1 was depleted. Similarly the CUE mutant, compared with the WT protein, showed decreased intensity at laser-induced sites of damage npg a r t i c l e s (Fig. 7d) . The recruitment of CUEm SMARCAD1 was not further decreased by depletion of BARD1, thereby suggesting that BARD1 and the CUE domains affect SMARCAD1 accumulation through the same pathway (Fig. 7d) . Pretreatment of cells with KU55933, a specific inhibitor ATM 36 , substantially diminished the formation of γ-H2AX from the path of the laser line, and it also sustainably decreased SMARCAD1 accumulation (Fig. 7d) . Thus, although BRCA1-BARD1 and SMARCAD1 CUE domains support SMARCAD1 recruitment, other ATM-dependent events are also required. We further tested the relationship between BRCA1-BARD1 and SMARCAD1. We found that although SMARCAD1 depletion alone decreased drug resistance and HR, this effect was not more pronounced in cells also lacking BRCA1-BARD1 activity ( Supplementary Fig. 8a,b) , thus suggesting that SMARCAD1 and BRCA1-BARD1 ligase activity influence drug resistance through the same pathway. Moreover H2A-Ub expression was unable to restore RAD51 foci levels in BARD1-depleted cells that were also depleted of SMARCAD1 (Supplementary Fig. 8c ). This evidence suggests a requirement for SMARCAD1 downstream of BRCA1-BARD1 ligase activity and C-terminal H2A ubiquitination. From these data, we predicted that SMARCAD1 and BRCA1-BARD1 have similar functions in resection and HR, and we therefore examined the relationship with 53BP1 in resection and in IRIF. Loss of 53BP1 restored full BrdU resection lengths to SMARCAD1-depleted cells (Fig. 7e) , thus suggesting that an antagonistic relationship between SMARCAD1 and 53BP1 regulates resection. Moreover, in S-phase or G2-phase SMARCAD-depleted cells, we observed that 53BP1 was not evicted to the periphery of BRCA1-associated foci, a result indicating that SMARCAD1 is also required for 53BP1 repositioning (Fig. 7f) . Expression of an siRNA-resistant WT SMARCAD1 protein restored normal distribution of 53BP1, but expression of the CUEm SMARCAD1 or an ATPase-dead form (K528R) did not ( Fig. 7f and Supplementary Fig. 8d ), thus indicating that both the CUE domains and enzymatic activity are required for repositioning 53BP1. Because the effect was not partial, these data also suggest that the CUE domains have a role in promoting 53BP1 repositioning beyond supporting the accumulation of SMARCAD1 at sites of damage.
In complementation of cells depleted of endogenous SMARCAD1, we found that CUEm SMARCAD1 was unable to restore RAD51 foci in irradiation-treated cells, and neither CUEm SMARCAD1 nor the ATPase-dead-mutant form restored the olaparib or camptothecin resistance of SMARCAD1-depleted cells (Fig. 7g and  Supplementary Fig. 8e) . Thus, the SMARCAD1 CUE domains are essential to promoting HR, consistently with their role in 53BP1 repositioning and drug resistance. As anticipated, the need for the SMARCAD1 CUE domains in promoting HR, as measured by RAD51 IRIF formation, was bypassed by treatment with siRNA to 53BP1 (Fig. 7g) . Similarly the repression of 53BP1 restored cellular olaparib and camptothecin resistance in SMARCAD-depleted cells (Fig. 7h) , thus confirming that SMARCAD1 is less important to cell survival when 53BP1 is absent. Together, these data confirm a link between BRCA1-BARD1 and SMARCAD1 in promoting resection in the presence of 53BP1.
DISCUSSION
Our data provided insight into how BRCA1 inhibits the 53BP1-complex-mediated block on resection. The BRCA1-BARD1 Ub ligase promotes a subset of DNA-repair functions attributed to BRCA1 and participates in promoting resection steps after CtIP-and MRE11-mediated commitment to HR. Consistently with the restoration of HR in BRCA1-BARD1 deficient cells, our results suggested that H2A-Ub complementation functions at the level of resection restoration. Initially we were surprised that our data indicated that C-terminal Ub modification of H2A is unlikely to directly inhibit the 53BP1 interactions. Instead, we found that promotion of HR requires the Ub-binding CUE domains of the chromatin remodeler SMARCAD1. Critically, both BRCA1 ligase activity and SMARCAD1 reposition 53BP1 within IRIF, and this repositioning correlates with the promotion of resection.
Our data suggest a model in which the BRCA1-BARD1 ligase modifies chromatin, thereby promoting the accumulation and activity of the chromatin remodeler SMARCAD1, which then mobilizes 53BP1 and allows the completion of resection (Fig. 8) . We suggest that BRCA1 activity, through this mechanism, promotes HR and inhibits toxic end-joining. Our model does not exclude an additional role for the observed 53BP1 ubiquitination, but notably H2A-Ub is sufficient to restore HR to near-normal levels in BRCA1-BARD1-deficient cells.
Yeast Fun30 can both slide nucleosomes and evict histone H2A and H2B dimers 37, 38 ; hence, whether SMARCAD1 shunts or removes DNA-damage-proximal histones is not yet known. Conceptually, nucleosome sliding may be inhibited by upstream nucleosomes, and eviction is a simpler model. In yeast, histones remain bound to DSB ends for a longer amount of time in fun30∆ cells 31 . In either case, remodeled nucleosomes may be those loaded with 53BP1 or may become refractory to 53BP1 interaction. SMARCAD1 is also required in the reestablishment of silent heterochromatin after DNA replication 39 . It will be intriguing to determine whether decreased SMARCAD1 activity at chromatin contributes to the decreased heterochromatin observed in Brca1-deficient mouse cells 9 .
We showed that cell survival in response to some DNA-damaging agents requires BRCA1 ligase function to counter 53BP1, whereas the responses to other agents, which induce replicative stress or intrastrand cross-links, are independent of this pathway. This information may provide a rationale for tailored anticancer treatment for some BRCA1-mutation carriers, because targeting ligase-dependent and npg a r t i c l e s ligase-independent aspects of the BRCA1 defect would be expected to slow the development of tumor resistance through 53BP1-complex downregulation or mutation. Several BRCA1 missense variants occur in the N terminus and have the potential to disrupt E3 Ub ligase function 16 . The role identified here for the ligase activity in promoting HR suggests a possible role in cancer protection. In defining the Ub-priming face of this and other type 1 E3 Ub ligases, our data provide a robust new means by which the ligase function can be assessed in cells and organisms.
METHODS
Methods and any associated references are available in the online version of the paper.
